Abstract 2254
Background
5-year survival with platinum-based combination chemotherapies in testicular cancer is 95%. Existing prognostic scoring scales may be insufficient to predict which patient will benefit from treatment. Additional prognostic factors should be determined. Unlike left testicular vein, right testicular vein drains to vena cava. Therefore, the systemic spread of the testicular cancers of each side considered to be different due to the difference of vascular structures of the right and left testis. In this study, we aimed to investigate the effects of tumor localization on survival in patients with nonseminomatous testicular cancer.
Methods
We enrolled 321 non-seminomatous testicular cancer patients who followed up at Gulhane Research and Training Hospital in between January 1981, and December 2015. We retrospectively obtained data of demographic features, histopathological results, information of surgical operations and chemo-radiotherapy protocols, history of autologous stem cell transplantation from patients’ files.
Results
We enrolled 321 non-seminomatous testicular carcinoma patients and summarized demographic information and treatment methods in the table. Median age was 34 (18-77) years. The primary tumor was in left testis in 152 (47.2%) patients and in right testis in 170 (52.8%) patients. The most common histopathological diagnosis was mixed non-seminomatous germ cell tumor (39.4%). One hundred forty-six (44.3%) cases were metastatic at the time of diagnosis. Median follow-up period was 88.3 months (1-386). Median 10-year survival rate was 74.1%, and the 20-year survival rate was 70.7%. We examined the effect of primary tumor localization and found that primary tumor localization was significantly different regarding survival between left and right testis (337.6 months vs. NR, p = 0.001). In patients with a right testicular tumor the recurrence rate was significantly higher (84.7% vs. 68.2%; p = 0.002).
Conclusions
The localization of primary testicular tumor (left or right) was statistically significant regarding survival. The effect of tumor localization on survival was independent of the presence of metastasis at the time of diagnosis, histopathological type, site of metastasis, and disease stage.
Clinical trial identification
.
Editorial acknowledgement
Legal entity responsible for the study
Gulhane Education and Research Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract